ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,930.85
1.09%
US Tech 100
20,836.00
1.31%
Dow Jones
42,840.26
1.18%
Brent Oil
72.72
0.00%
Bitcoin
96,088.21
-1.15%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Krystal Biotech Inc (KRYS) Quote

Krystal Biotech Inc

Krystal Biotech Inc (KRYS)

NASDAQ
164.83
4.00
(2.49%)
Closed December 22 4:00PM
Delayed by 15 minutes
164.8305
0.0005
(0.00%)
After Hours: 7:59PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
164.83
Bid
153.79
Ask
174.62
Volume
864,667
160.57 Day's Range 165.98
107.50 52 Week Range 219.34
Market Cap
4.741B
Previous Close
160.83
Open
160.57
Last Trade
6081
@
164.83
(average)
Last Trade Time
Financial Volume
$ 141,552,231
VWAP
163.7072
Average Volume (3m)
232,941
Shares Outstanding
28,760,548
Dividend Yield
-
PE Ratio
433.44
Earnings Per Share (EPS)
0.38
Revenue
50.7M
Net Profit
10.93M

About Krystal Biotech Inc

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments... Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.krystalbio.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Krystal Biotech Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker KRYS. The last closing price for Krystal Biotech was $160.83. Over the last year, Krystal Biotech shares have traded in a share price range of $ 107.50 to $ 219.34.

Krystal Biotech currently has 28,760,548 shares outstanding. The market capitalization of Krystal Biotech is $4.63 billion. Krystal Biotech has a price to earnings ratio (PE ratio) of 433.44.

Ask ADVFN Intelligence (AI)

Krystal Biotech (KRYS) Options Flow Summary

KRYS Options Flow

Overall Flow

Bearish

Net Premium

-2M

Calls / Puts

2.13%

Buys / Sells

220.00%

OTM / ITM

4.35%

Sweeps Ratio

0.00%

KRYS Latest News

More News

Form 8-K - Current report

December 18 2024
Edgar (US Regulatory)

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful...

December 18 2024
GlobeNewswire Inc.

Form 8-K - Current report

December 12 2024
Edgar (US Regulatory)

Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels

Clear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients Both KB408 for AATD patients and KB407 for patients with cystic fibrosis were safe and...

December 12 2024
GlobeNewswire Inc.

Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the...

December 09 2024
GlobeNewswire Inc.

Krystal Biotech to Present at Upcoming Investor Conferences

PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and...

November 27 2024
GlobeNewswire Inc.

Krystal Biotech to Present at Stifel 2024 Healthcare Conference

PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in...

November 12 2024
GlobeNewswire Inc.

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in...

November 06 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 04 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 04 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-6.93-4.03469958081171.76174.565155.16389183163.08997106CS
4-19.24-10.4525452274184.07200155.16276513178.08187879CS
12-15.42-8.5547850208180.25207.84155.16232941178.60468092CS
26-7.6-4.40758568695172.43219.34155.16294022184.4712952CS
5246.3139.0735740803118.52219.34107.5320975167.90340555CS
15694.36133.90095075970.47219.3447.67257831122.02806291CS
260108.93194.86583184355.9219.3433.0848226076102.1272659CS

KRYS - Frequently Asked Questions (FAQ)

What is the current Krystal Biotech share price?
The current share price of Krystal Biotech is $ 164.83
How many Krystal Biotech shares are in issue?
Krystal Biotech has 28,760,548 shares in issue
What is the market cap of Krystal Biotech?
The market capitalisation of Krystal Biotech is USD 4.63B
What is the 1 year trading range for Krystal Biotech share price?
Krystal Biotech has traded in the range of $ 107.50 to $ 219.34 during the past year
What is the PE ratio of Krystal Biotech?
The price to earnings ratio of Krystal Biotech is 433.44
What is the cash to sales ratio of Krystal Biotech?
The cash to sales ratio of Krystal Biotech is 93.46
What is the reporting currency for Krystal Biotech?
Krystal Biotech reports financial results in USD
What is the latest annual turnover for Krystal Biotech?
The latest annual turnover of Krystal Biotech is USD 50.7M
What is the latest annual profit for Krystal Biotech?
The latest annual profit of Krystal Biotech is USD 10.93M
What is the registered address of Krystal Biotech?
The registered address for Krystal Biotech is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Krystal Biotech website address?
The website address for Krystal Biotech is www.krystalbio.com
Which industry sector does Krystal Biotech operate in?
Krystal Biotech operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
$ 0.4603
(-71.41%)
27.5M
MTEMMolecular Templates Inc
$ 0.1502
(-57.09%)
8.63M
PRFXPainReform Ltd
$ 5.15
(-53.85%)
2.84M
GALTGalectin Therapeutics Inc
$ 1.03
(-48.50%)
8.58M
BCABBioAtla Inc
$ 0.6923
(-41.82%)
5.96M
EDBLEdible Garden AG Inc
$ 0.24
(65.06%)
354.33M
NVDANVIDIA Corporation
$ 134.70
(3.08%)
310.19M
APTOAptose Biosciences Inc
$ 0.28
(64.51%)
306.25M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.606999
(6.49%)
293.22M
PLTRPalantir Technologies Inc
$ 80.55
(8.54%)
281.23M

KRYS Discussion

View Posts
Monksdream Monksdream 2 months ago
KRYS. Under $200
👍️0
Monksdream Monksdream 5 months ago
KRYS new 52 week high
👍️0
Monksdream Monksdream 8 months ago
KRYS 10Q due 5/6
👍️0
Monksdream Monksdream 9 months ago
KRYS over $30
👍️0
Monksdream Monksdream 10 months ago
KRYS new 52 week high
👍️0
Monksdream Monksdream 1 year ago
From Cathie Wood
A Novel Gene Therapy Promises Relief For A Rare Genetic Skin Disorder
ARK Invest_Illustration_Pierce Jamieson_Final_Circle 400 px By Pierce Jamieson | @PierceARK
Research Associate
Recently, the US Food and Drug Administration (FDA) approved Krysta Biotech’s (KRYS) groundbreaking advance1 in gene therapy, Vyjuvek, to treat wounds in patients suffering from dystrophic epidermolysis bullosa (DEB), a rare and serious genetic skin disorder caused by mutations in the collagen Type VII alpha 1 chain (COL7A1) gene. As the first FDA-approved gene therapy for DEB, Vyjuvek is a significant breakthrough.

Vyjuvek uses a genetically modified HSV-1 to deliver normal copies of the COL7A1 gene to wounds, restoring the integrity of the skin with fibrils that hold skin layers together. Treated with Vyjuvek, 65% of wounds closed completely.
👍️0
wiredawg wiredawg 3 years ago
Moving nicely today...
👍️0
wiredawg wiredawg 3 years ago
Looking at the few posts here there seems to be no real commitment here...any thoughts on KRYS? Hype or something brewing?
👍️0
wiredawg wiredawg 3 years ago
In the last 3 months, 5 ranked analysts set 12-month price targets for KRYS. The average price target among the analysts is $125.00. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price. High $140 Low $111

👍️0
wiredawg wiredawg 3 years ago
30 Nov Tues releases this PR during evening after market close:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-pricing-200-million-public-offering
👍️0
wiredawg wiredawg 3 years ago
29 Nov Mon after market closes release this PR:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-proposed-200-million-public-offering
👍️0
wiredawg wiredawg 3 years ago
29 Nov Monday pre-market news release, great move pre-market approx 7am and so far holding fairly well:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-topline-results-gem-3-pivotal
👍️0
wiredawg wiredawg 3 years ago
This caught my eye on Monday, the huge move off the PR...I'm guessing here saw the same. Any real thoughts regarding the company and this PR. I have not gotten a chance to dig into it. Hoping to have somm DD done over the weekend.
👍️0
wiredawg wiredawg 3 years ago
Holding well so far, why the pretty hard drop?
👍️0
wiredawg wiredawg 3 years ago
Why are you surprised? Serious question, not being impudent...
👍️0
rynlrt rynlrt 3 years ago
200 million dollar offering. Won't be surprised to see it drop pretty hard when the market opens
👍️0
Fofo812 Fofo812 3 years ago
Surprised it held up this long
👍️0
crudeoil24 crudeoil24 3 years ago
Large tutes holdings. Some taking huge gains before years end.
👍️0
rynlrt rynlrt 3 years ago
Not sure this kind of gain is sustainable. May see a big pullback
👍️0
Fofo812 Fofo812 3 years ago
3rd post
👍️0
crudeoil24 crudeoil24 3 years ago
Krystal Biotech shares are trading higher after the company announced its GEM-3 trial met its primary endpoint.
👍️0
Trophy Trophy 5 years ago
..
👍️0

Your Recent History

NASDAQ
KRYS
Krystal Biotech
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads